What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Psychiatry
- Disease
David A. Fiellin mostly deals with Buprenorphine, Psychiatry, Anesthesia, Opioid and Substance abuse.
His Buprenorphine research incorporates elements of Clinical trial, Heroin, Randomized controlled trial, Emergency medicine and Naloxone.
His studies deal with areas such as Medical prescription and Public health as well as Psychiatry.
His work deals with themes such as Opioid analgesics and Naltrexone, which intersect with Anesthesia.
David A. Fiellin has researched Opioid in several fields, including Cross-sectional study, Hiv status, Physical therapy, Chronic pain and Addiction.
His research in Substance abuse intersects with topics in Young adult, -Naloxone, Acquired immunodeficiency syndrome and Cohort study.
His most cited work include:
- Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. (613 citations)
- Screening for Alcohol Problems in Primary Care: A Systematic Review (554 citations)
- Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial (360 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Psychiatry, Buprenorphine, Internal medicine, Opioid and Cohort study.
In his study, which falls under the umbrella issue of Psychiatry, Emergency medicine is strongly linked to Medical prescription.
The Buprenorphine study combines topics in areas such as Methadone, Anesthesia, Opioid use disorder, Randomized controlled trial and Naloxone.
His Randomized controlled trial research integrates issues from Clinical trial and Abstinence.
He interconnects Chronic pain and Intensive care medicine in the investigation of issues within Opioid.
His work carried out in the field of Substance abuse brings together such families of science as Acquired immunodeficiency syndrome and Family medicine.
He most often published in these fields:
- Psychiatry (30.47%)
- Buprenorphine (28.39%)
- Internal medicine (23.96%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (23.96%)
- Cohort study (18.23%)
- Opioid use disorder (9.64%)
In recent papers he was focusing on the following fields of study:
David A. Fiellin spends much of his time researching Internal medicine, Cohort study, Opioid use disorder, Opioid and Buprenorphine.
The study incorporates disciplines such as Medical prescription, Poisson regression and Substance abuse in addition to Internal medicine.
His Medical prescription research focuses on Emergency medicine and how it connects with Prospective cohort study.
His research integrates issues of Psychological intervention, Heroin, Emergency department and Family medicine, Referral in his study of Opioid use disorder.
His studies examine the connections between Opioid and genetics, as well as such issues in Incidence, with regards to Injury prevention and Public health.
His studies in Buprenorphine integrate themes in fields like Methadone, Psychiatry and Opioid Agonist.
Between 2017 and 2021, his most popular works were:
- When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis. (73 citations)
- Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. (46 citations)
- Women and opioids: something different is happening here (33 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Psychiatry
- Disease
His primary areas of investigation include Cohort study, Internal medicine, Opioid use disorder, Opioid and Viral load.
The concepts of his Cohort study study are interwoven with issues in Prospective cohort study, Confidence interval, Public health, Medical prescription and Cohort.
His Medical prescription research includes themes of Heroin and Emergency medicine.
His Internal medicine study combines topics in areas such as Acquired immunodeficiency syndrome and Medicaid.
His Opioid use disorder study incorporates themes from Buprenorphine, Hepatitis C, Randomized controlled trial and Referral.
David A. Fiellin combines subjects such as Methadone, Emergency department and Family medicine with his study of Buprenorphine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
